Delta/Omicron BA.1 coinfection/ previously vaccinated with two doses of the Pfizer/ BioNTech COVID-19 vaccination almost a year prior; Delta/Omicron BA.1 coinfection/ previously vaccinated with two doses of the Pfizer/ BioNTech COVID-19 vaccination almost a year prior; This is a literature report for the following literature source(s):   A 70-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "uncontrolled type II diabetes" (ongoing); "loss of taste" (unspecified if ongoing); "persistent cough" (unspecified if ongoing). The patient's concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant) with onset Jan2022, outcome "unknown", COVID-19 (hospitalization, medically significant) with onset Jan2022, outcome "recovered" (2022) and all described as "Delta/Omicron BA.1 coinfection/ previously vaccinated with two doses of the Pfizer/ BioNTech COVID-19 vaccination almost a year prior". The patient was hospitalized for drug ineffective, covid-19 (hospitalization duration: 3 day(s)). The patient underwent the following laboratory tests and procedures: Blood glucose: (Jan2022) hyperglycemic; Body temperature: (Jan2022) unknown results, notes: afebrile; SARS-CoV-2 test: (Jan2022) Delta/Omicron BA.1; Serology test: (Jan2022) unknown result. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  Clinical course: An additional Delta/Omicron BA.1 coinfection in a 70-year-old female with uncontrolled type II diabetes. This case was notable as it occurred overlapped temporally with the coinfection at the beginning of January 2022 when both the Delta and Omicron BA.1 VOCs were present in the community in relative abundance. Upon presentation the patient was afebrile but complained of a loss of taste and persistent cough. The patient was previously vaccinated with two doses of the Pfizer/ BioNTech COVID-19 vaccination almost a year prior, but her serological status was unknown. At the time of presentation, the patient was profoundly hyperglycemic which can impact immune function. Type II diabetes is a risk factor for more severe COVID-19. Thus, while not having underlying malignancy or managed with immunosuppressive drugs as others in this case series, this patient's immune status was likely dysregulated due to her comorbidity which can render her more susceptible to infection. This patient was managed without COVID-19 specific therapy and discharged 3 days later. As before, no mutational signatures consistent with SARS-CoV-2 recombination were identified in this patient's respiratory specimens.  The lot number for BNT162b2 was not provided and will be requested during follow up.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to its Lack of efficacy cannot be ruled out.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201301194 Same article/ drug/event and different patient;